PZM21

Product Description

PZM21 is a selective μ receptor agonist (EC₅₀ = 4.6 nM). PZM21 has been reported to exhibit bias for the G_i signaling pathway over arrestin-3. The compound exhibits 500-fold selectivity for μ over δ receptors and no detectable activity at κ or nociceptin receptors and a panel of 316 other GPCRs. PZM21 induces analgesia in a mouse hot plate assay, but not a tail-flick assay and exhibits no significant conditioned place preference response in in vivo assays. CNS penetrant.

Solubility

Preparing Stock Solutions for PZM21

The following data is based on the product molecular weight 361.50

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.77 mL	13.83 mL	27.66 mL
5 mM	0.55 mL	2.77 mL	5.53 mL
10 mM	0.28 mL	1.38 mL	2.77 mL
50 mM	0.06 mL	0.28 mL	0.55 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Hill The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. Br.J.Pharmacol. 2018 PMID: 29582414
• Manglik Structure-based discovery of opioid analgesics with reduced side effects. Nature 2016 PMID: 27533032